Grip Molecular Technologies
Biotechnology, 1000 Westgate Dr, St Paul, Minnesota, 55114, United States, 1-10 Employees
Who is GRIP MOLECULAR TECHNOLOGIES
GRIP Molecular is developing a novel, patent-protected, chip-based electronic biosensor that will provide lab-grade diagnostic results in minutes using a mobile device at the point of nee...
Read More
-
Headquarters: 1000 Westgate Dr, St Paul, Minnesota, 55114, United States
-
Date Founded: 2019
-
Employees: 1-10
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 3845
|
NAICS Code: 334510 |
Show More
Does something look wrong? Fix it. | View contact records from GRIP MOLECULAR TECHNOLOGIES
GRIP Molecular Technologies Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding GRIP Molecular Technologies
Answer: GRIP Molecular Technologies's headquarters are located at 1000 Westgate Dr, St Paul, Minnesota, 55114, United States
Answer: GRIP Molecular Technologies's official website is https://gripmolecular.com
Answer: GRIP Molecular Technologies's revenue is $1 Million to $5 Million
Answer: GRIP Molecular Technologies's SIC: 3845
Answer: GRIP Molecular Technologies's NAICS: 334510
Answer: GRIP Molecular Technologies has 1-10 employees
Answer: GRIP Molecular Technologies is in Biotechnology
Answer: GRIP Molecular Technologies contact info: Phone number: Website: https://gripmolecular.com
Answer: GRIP Molecular is developing a novel, patent-protected, chip-based electronic biosensor that will provide lab-grade diagnostic results in minutes using a mobile device at the point of need. Unlike existing diagnostic technologies, it has the capability to simultaneously detect various diseases and characterize their state of infection (infectious to immune) with a single test. GRIP uses a combination of novel nanomaterials and patented 3D printing to deliver accurate results in minutes without the burden of complex chemistry. The appearance of COVID-19 as a global health threat has increased the urgency to transform diagnostics, which the GRIP team was well into even before this threat emerged. The ability to quickly, easily and cost-effectively test for active infection and immunity at the point of need has become the new baseline for what we should expect for early detection of all kinds of disease, but particularly when fighting a pandemic level enemy. GRIP is committed to confirm the science and commercialize a new approach with a number of specific panels/products that address our most challenging diseases and chronic conditions.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month